Welcome to our dedicated page for LifeStance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. has a significant shareholder group led by TPG GP A, LLC, together with James G. Coulter and Jon Winkelried as reporting persons. Through TPG VIII Lynnwood Holdings Aggregation, L.P., they report beneficial ownership of 98,101,407 shares of common stock.
This represents 25.7% of LifeStance’s common stock, based on 382,055,609 shares outstanding as of July 29, 2026. The shares are held indirectly through a chain of TPG entities, with voting and dispositive power shared among the reporting persons, who each disclaim beneficial ownership beyond their pecuniary interest.
Yawaog Enterprises Corp reported a planned sale of common stock under Rule 144. The reporting holder intends to sell 7,500 common shares through Fidelity Brokerage Services LLC on NASDAQ, with an indicated aggregate market value of $95,118.49 as of the proposed transaction.
The shares to be sold arise from restricted stock vesting on June 1, 2025, classified as compensation from the issuer. The filing also notes a prior sale of 20,441 common shares on August 13, 2026 for $249,993.43 during the preceding three months.
LifeStance Health Group, Inc. director Kenneth A. Burdick reported a sale of 500,000 shares of common stock on 2026-08-11 at a weighted average price of $11.51 per share, with individual trades between $11.50 and $11.665. Following this sale, he directly holds 2,970,810 shares and indirectly holds 46,511 shares through Burdick Family LLC.
LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich reported selling 44,394 shares of common stock on August 10, 2026, at $10.85 per share in an open market or private transaction. After this transaction, he directly holds 247,446 shares. The transaction is flagged as made pursuant to a Rule 10b5-1 trading plan, indicating it was executed under a pre-arranged plan.
LifeStance Health Group, Inc. reported that entities associated with TPG sold 13,643,207 shares of Common Stock at $10.62 per share in an indirect transaction. After this sale, TPG VIII Lynnwood Holdings Aggregation, L.P. directly holds 98,101,407 LifeStance common shares. The reporting persons are treated as indirect holders through a multi‑entity ownership chain and each disclaims beneficial ownership beyond any pecuniary interest.
LifeStance Health Group, Inc. reported that Chief Operating Officer Lisa K. Miller sold 47,912 shares of common stock on August 10, 2026 at $10.85 per share in an open-market or private transaction. After this sale, she directly holds 281,289 shares of LifeStance common stock. The transaction was affirmed as being made pursuant to a Rule 10b5-1 trading plan.
A holder of LFST common stock has filed to potentially sell up to 500,000 shares through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $5,756,737.55. The issuer had 382,055,609 common shares outstanding. The shares to be sold include stock received as restricted stock vesting on March 6, 2025 for 82,616 shares and on March 7, 2025 for 417,384 shares, both described as compensation.
LifeStance Health Group, Inc. is the subject of an amended Schedule 13G filing by a group of Summit Partners-affiliated investment funds reporting passive beneficial ownership of its common stock. The reporting group, led by Summit Partners, L.P., reports beneficial ownership of 23,310,115 shares of common stock, representing 6.10% of the class, based on 382,055,609 shares outstanding as of July 29, 2026.
The individual Summit funds report shared voting and dispositive power over their respective positions, including 14,274,150 shares (3.74%) held by Summit Partners Growth Equity Fund IX-A, L.P. and 8,912,582 shares (2.33%) held by Summit Partners Growth Equity Fund IX-B, L.P. Smaller positions are reported by related Summit entities. Investment and voting decisions for the reported securities are delegated to Summit Partners, L.P. through a three-person investment committee. The reporting entities and committee members expressly disclaim beneficial ownership beyond what is reported for purposes of Section 13(d) and 13(g).
LFST received a Rule 144 notice indicating that Citadel Securities, LLC plans to sell up to 13,643,207 shares of Common Stock, par value $0.01 per share, on the NASDAQGS on or after August 10, 2026. The filing lists an aggregate market value of $147,892,363.88 for these shares, with 382,055,609 shares of Common Stock outstanding. The seller originally acquired 184,902,826 shares from the issuer on June 9, 2021 in a reorganization that preceded the company’s initial public offering, described as a contribution of limited partner interests for shares of Common Stock.